Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36 mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations. Management raised 2025 guidance to ranges of $60 billion-$62 billion in revenue ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In the 72-week phase 3 ATTAIN-1 trial, the once-daily oral GLP-1 receptor agonist orforglipron led to substantial weight loss ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...